{"id":1821,"date":"2026-04-23T19:04:16","date_gmt":"2026-04-23T19:04:16","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-05-05T14:41:33","modified_gmt":"2026-05-05T14:41:33","slug":"epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance","status":"publish","type":"post","link":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/","title":{"rendered":"Epitopea annonce l&#8217;approbation de la demande d&#8217;essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l&#8217;ovaire s\u00e9reux de haut grade avanc\u00e9"},"content":{"rendered":"\n<p><strong>CAMBRIDGE, ROYAUME-UNI et MONTR\u00c9AL, CANADA, 23 avril 2026&nbsp;<\/strong>\u2013 Epitopea, une soci\u00e9t\u00e9 biotechnologique transatlantique d\u00e9veloppant des immunoth\u00e9rapies anticanc\u00e9reuses pr\u00eates \u00e0 l&#8217;emploi, durables et \u00e0 base d&#8217;ARN, a annonc\u00e9 aujourd&#8217;hui avoir re\u00e7u l&#8217;approbation de l&#8217;Agence britannique de r\u00e9glementation des m\u00e9dicaments et des produits de sant\u00e9 (MHRA) et du Comit\u00e9 d\u2019\u00e9thique r\u00e9gional (REC) pour sa demande d\u2019essai clinique (CTA) concernant son premier essai clinique chez l\u2019humain (OVACT) de son programme phare, CryptiVax<sup>MC<\/sup>-1001, ciblant le cancer de l\u2019ovaire s\u00e9reux de haut grade \u00e0 un stade avanc\u00e9.<\/p>\n\n\n\n<p>Epitopea annonce \u00e9galement la nomination de la professeure Susana Banerjee (MBBS, MA, PhD, FRCP), oncologue m\u00e9dicale consultante et responsable de la recherche au sein de l\u2019unit\u00e9 de gyn\u00e9cologie&nbsp;<a href=\"https:\/\/www.royalmarsden.nhs.uk\/\" rel=\"noreferrer noopener\" target=\"_blank\">du Royal Marsden<\/a>&nbsp;NHS Foundation Trust, ainsi que professeure sp\u00e9cialis\u00e9e dans les cancers f\u00e9minins \u00e0 l\u2019Institute of Cancer Research, au poste de chercheuse principale de l\u2019essai OVACT.<\/p>\n\n\n\n<p>Le Dr Klaus Edvardsen, MD, directeur m\u00e9dical d\u2019Epitopea, a d\u00e9clar\u00e9 : \u00ab Nous sommes ravis d\u2019avoir franchi cette \u00e9tape r\u00e9glementaire importante, qui rend hommage \u00e0 notre \u00e9quipe clinique d\u00e9vou\u00e9e et \u00e0 l\u2019ensemble de l\u2019\u00e9quipe d\u2019Epitopea. Nous souhaitons \u00e9galement la bienvenue \u00e0 la professeure Banerjee dans son r\u00f4le de chercheuse principale de notre premier essai clinique. Son expertise de classe mondiale dans le domaine du cancer de l\u2019ovaire et son leadership en mati\u00e8re de d\u00e9veloppement clinique mondial apporteront des connaissances inestimables alors que nous passons au statut d\u2019entreprise en phase clinique. \u00bb<\/p>\n\n\n\n<p>OVACT est un essai de phase 1\/1b \u00e0 escalade de dose et d&#8217;extension, con\u00e7u pour \u00e9valuer la s\u00e9curit\u00e9, la tol\u00e9rance, l&#8217;immunog\u00e9nicit\u00e9 et l&#8217;activit\u00e9 clinique pr\u00e9coce de CryptiVax<sup>MC<\/sup>-1001 chez des patientes atteintes d&#8217;un cancer de l&#8217;ovaire s\u00e9reux de haut grade HRP+\/BRCA- de type sauvage.<\/p>\n\n\n\n<p>Le cancer de l&#8217;ovaire s\u00e9reux de haut grade (HGSOC) reste l&#8217;une des tumeurs solides les plus difficiles \u00e0 traiter, la plupart des patientes (~80 %) pr\u00e9sentant une maladie avanc\u00e9e ou m\u00e9tastatique. Si la plupart des femmes r\u00e9pondent \u00e0 la chimioth\u00e9rapie de premi\u00e8re ligne \u00e0 base de platine, presque toutes finissent par faire une rechute et d\u00e9veloppent une maladie r\u00e9sistante au platine. Les options de traitement d&#8217;entretien existantes laissent un vide th\u00e9rapeutique important chez les patientes HRP+\/BRCA- de type sauvage, qui repr\u00e9sentent environ la moiti\u00e9 de la population atteinte d&#8217;un cancer de l&#8217;ovaire.<\/p>\n\n\n\n<p>Le professeur Banerjee a ajout\u00e9 : \u00ab Il existe un besoin non satisfait important dans le cancer de l\u2019ovaire \u00e0 recombinaison homologue comp\u00e9tente (HRP), o\u00f9 les traitements d\u2019entretien disponibles n\u2019apportent qu\u2019un b\u00e9n\u00e9fice durable limit\u00e9. Le vaccin CryptiVax<sup>MC<\/sup>-1001 d\u2019Epitopea, qui cible un nouveau r\u00e9pertoire d\u2019antig\u00e8nes sp\u00e9cifiques \u00e0 la tumeur, a le potentiel de prolonger de mani\u00e8re significative la r\u00e9mission chez les patientes disposant de peu d\u2019options th\u00e9rapeutiques efficaces. \u00bb<\/p>\n\n\n\n<p>Le pipeline d\u2019Epitopea s\u2019appuie sur CryptoMap<sup>MC<\/sup>, un moteur de d\u00e9couverte propri\u00e9taire qui identifie les antig\u00e8nes pr\u00e9sent\u00e9s par la tumeur issus du g\u00e9nome sombre, une source jusqu\u2019alors inaccessible de nouvelles cibles sp\u00e9cifiques \u00e0 la tumeur. Ces antig\u00e8nes, appel\u00e9s Cryptigens<sup>MC<\/sup>, pr\u00e9sentent un degr\u00e9 \u00e9lev\u00e9 de partage entre les patients, ce qui permet le d\u00e9veloppement de v\u00e9ritables immunoth\u00e9rapies \u00e0 base d\u2019ARNm pr\u00eates \u00e0 l\u2019emploi.<\/p>\n\n\n\n<p><strong>\u00c0 propos d&#8217;Epitopea<\/strong><br>Epitopea est une soci\u00e9t\u00e9 transatlantique sp\u00e9cialis\u00e9e dans l\u2019immunoth\u00e9rapie anticanc\u00e9reuse qui d\u00e9veloppe des immunoth\u00e9rapies \u00e0 base d\u2019ARN accessibles et pr\u00eates \u00e0 l\u2019emploi pour les tumeurs solides difficiles \u00e0 traiter.&nbsp;Le pipeline d\u2019Epitopea repose sur les TSA Cryptigen<sup>MC<\/sup>, une nouvelle classe d\u2019antig\u00e8nes sp\u00e9cifiques aux tumeurs identifi\u00e9s par CryptoMap<sup>MC<\/sup>, la plateforme propri\u00e9taire d\u2019immunopeptidomique et de g\u00e9nomique de la soci\u00e9t\u00e9 qui met en \u00e9vidence des antig\u00e8nes exprim\u00e9s de mani\u00e8re aberrante provenant de r\u00e9gions du g\u00e9nome jusqu\u2019alors non caract\u00e9ris\u00e9es.<\/p>\n\n\n\n<p>Le principal candidat de la soci\u00e9t\u00e9, CryptiVax<sup>MC<\/sup>-1001, est un vaccin th\u00e9rapeutique \u00e0 ARNm pr\u00eat \u00e0 l&#8217;emploi en cours de d\u00e9veloppement pour le cancer de l&#8217;ovaire s\u00e9reux de haut grade. Il est con\u00e7u pour induire des r\u00e9ponses immunitaires cibl\u00e9es \u00e0 l&#8217;aide d&#8217;un ensemble d&#8217;antig\u00e8nes sp\u00e9cifiques \u00e0 la tumeur s\u00e9lectionn\u00e9s pour couvrir un large \u00e9ventail de patientes. De nombreux patients atteints de cancers avanc\u00e9s, y compris le cancer de l&#8217;ovaire s\u00e9reux de haut grade, disposent d&#8217;options th\u00e9rapeutiques durables limit\u00e9es et de peu de traitements efficaces en dehors des populations s\u00e9lectionn\u00e9es sur la base de biomarqueurs. Epitopea vise \u00e0 r\u00e9pondre \u00e0 ce besoin non satisfait gr\u00e2ce \u00e0 des immunoth\u00e9rapies largement applicables et s\u00e9lectives vis-\u00e0-vis des tumeurs.<br><br>Soutenue par des investisseurs de premier plan dans le domaine des sciences de la vie, Epitopea op\u00e8re depuis Cambridge, au Royaume-Uni, et Montr\u00e9al, au Canada. Pour plus d&#8217;informations, rendez-vous sur&nbsp;<a href=\"http:\/\/www.epitopea.com\/\" rel=\"noreferrer noopener\" target=\"_blank\"><strong>www.epitopea.com<\/strong><\/a>&nbsp;et suivez l&#8217;entreprise sur&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/epitopea\/?viewAsMember=true\" rel=\"noreferrer noopener\" target=\"_blank\"><strong>LinkedIn<\/strong><\/a>.<\/p>\n\n\n\n<p><strong>Pour plus d&#8217;informations<\/strong><br><strong>Epitopea&nbsp;<\/strong>&nbsp;<br>Dr Alan C. Rigby \u2013 PDG &nbsp;<br><a href=\"mailto:Alan.Rigby@epitopea.com\" rel=\"noreferrer noopener\" target=\"_blank\">Alan.Rigby@epitopea.com<\/a><\/p>\n\n\n\n<p><strong>Scius Communications (pour Epitopea)&nbsp;<\/strong>&nbsp;<br>Katja Stout &nbsp;<br>+44 7789 435990 &nbsp;<br><a href=\"mailto:katja@sciuscommunications.com\" rel=\"noreferrer noopener\" target=\"_blank\">katja@sciuscommunications.com<\/a><br><br>Daniel Gooch &nbsp;<br>+44 7747 875479 &nbsp;<br><a href=\"mailto:daniel@sciuscommunications.com\" rel=\"noreferrer noopener\" target=\"_blank\">daniel@sciuscommunications.com<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.epitopea.com\/fr\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/\">Lire le communiqu\u00e9 original<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, ROYAUME-UNI et MONTR\u00c9AL, CANADA, 23 avril 2026&nbsp;\u2013 Epitopea, une soci\u00e9t\u00e9 biotechnologique transatlantique d\u00e9veloppant des immunoth\u00e9rapies anticanc\u00e9reuses pr\u00eates \u00e0 l&#8217;emploi, durables et \u00e0 base d&#8217;ARN, a annonc\u00e9 aujourd&#8217;hui avoir re\u00e7u [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1889,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"company":[108],"class_list":["post-1821","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites-des-compagnies-du-portefeuille"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Epitopea annonce l&#039;approbation de la demande d&#039;essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l&#039;ovaire s\u00e9reux de haut grade avanc\u00e9 | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Epitopea annonce l&#039;approbation de la demande d&#039;essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l&#039;ovaire s\u00e9reux de haut grade avanc\u00e9 | adMare\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, ROYAUME-UNI et MONTR\u00c9AL, CANADA, 23 avril 2026&nbsp;\u2013 Epitopea, une soci\u00e9t\u00e9 biotechnologique transatlantique d\u00e9veloppant des immunoth\u00e9rapies anticanc\u00e9reuses pr\u00eates \u00e0 l&#8217;emploi, durables et \u00e0 base d&#8217;ARN, a annonc\u00e9 aujourd&#8217;hui avoir re\u00e7u [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-23T19:04:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-05T14:41:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopea-news-fr-1739974973.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"Epitopea annonce l&#8217;approbation de la demande d&#8217;essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l&#8217;ovaire s\u00e9reux de haut grade avanc\u00e9\",\"datePublished\":\"2026-04-23T19:04:16+00:00\",\"dateModified\":\"2026-05-05T14:41:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\\\/\"},\"wordCount\":927,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/epitopea-news-fr-1739974973.png\",\"articleSection\":[\"Actualit\u00e9s des compagnies du portefeuille\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\\\/\",\"name\":\"Epitopea annonce l'approbation de la demande d'essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l'ovaire s\u00e9reux de haut grade avanc\u00e9 | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/epitopea-news-fr-1739974973.png\",\"datePublished\":\"2026-04-23T19:04:16+00:00\",\"dateModified\":\"2026-05-05T14:41:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/epitopea-news-fr-1739974973.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/epitopea-news-fr-1739974973.png\",\"width\":1200,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Epitopea annonce l&#8217;approbation de la demande d&#8217;essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l&#8217;ovaire s\u00e9reux de haut grade avanc\u00e9\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Epitopea annonce l'approbation de la demande d'essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l'ovaire s\u00e9reux de haut grade avanc\u00e9 | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Epitopea annonce l'approbation de la demande d'essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l'ovaire s\u00e9reux de haut grade avanc\u00e9 | adMare","og_description":"CAMBRIDGE, ROYAUME-UNI et MONTR\u00c9AL, CANADA, 23 avril 2026&nbsp;\u2013 Epitopea, une soci\u00e9t\u00e9 biotechnologique transatlantique d\u00e9veloppant des immunoth\u00e9rapies anticanc\u00e9reuses pr\u00eates \u00e0 l&#8217;emploi, durables et \u00e0 base d&#8217;ARN, a annonc\u00e9 aujourd&#8217;hui avoir re\u00e7u [&hellip;]","og_url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/","og_site_name":"adMare","article_published_time":"2026-04-23T19:04:16+00:00","article_modified_time":"2026-05-05T14:41:33+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopea-news-fr-1739974973.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"Epitopea annonce l&#8217;approbation de la demande d&#8217;essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l&#8217;ovaire s\u00e9reux de haut grade avanc\u00e9","datePublished":"2026-04-23T19:04:16+00:00","dateModified":"2026-05-05T14:41:33+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/"},"wordCount":927,"publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopea-news-fr-1739974973.png","articleSection":["Actualit\u00e9s des compagnies du portefeuille"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/","url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/","name":"Epitopea annonce l'approbation de la demande d'essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l'ovaire s\u00e9reux de haut grade avanc\u00e9 | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopea-news-fr-1739974973.png","datePublished":"2026-04-23T19:04:16+00:00","dateModified":"2026-05-05T14:41:33+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopea-news-fr-1739974973.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopea-news-fr-1739974973.png","width":1200,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/fr\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/fr\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/fr\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Epitopea annonce l&#8217;approbation de la demande d&#8217;essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l&#8217;ovaire s\u00e9reux de haut grade avanc\u00e9"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/fr\/#website","url":"https:\/\/admarebio.com\/fr\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/fr\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/comments?post=1821"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1821\/revisions"}],"predecessor-version":[{"id":1822,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1821\/revisions\/1822"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media\/1889"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media?parent=1821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/categories?post=1821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/tags?post=1821"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/company?post=1821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}